The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 15-21

  Wu, Qinghua ^a   Suo, Zhenhe ^a   Kristensen, Gunnar B ^b   Baekelandt, Mark ^b   Nesland, Jahn M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

EphB2; EphB4; Immunohistochemistry; Ovarian carcinoma; RT PCR

Indexed keywords

EPHRIN RECEPTOR; EPHRINE B2 RECEPTOR; EPHRINE B4 RECEPTOR; MESSENGER RNA; PLATINUM DERIVATIVE; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TISSUE LEVEL; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTOR, EPHB2; RECEPTOR, EPHB4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 33744910085     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.034     Document Type: Article

References (48)

1. Hunter T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect. 94 (1998) 81-119
2. Robinson D.R., Wu Y.M., and Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 19 (2000) 5548-5557
3. Kolibaba K.S., and Druker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333 (1997) F217-F248
4. Robertson S.C., Tynan J.A., and Donoghue D.J. Rtk mutations and human syndromes when good receptors turn bad. Trends Genet. 16 (2000) 265-271
5. Tuzi N.L., and Gullick W.J. Eph, the largest known family of putative growth factor receptors. Br. J. Cancer 69 (1994) 417-421
6. Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17 (1996) 9-19
7. Himanen J.P., Chumley M.J., Lackmann M., Li C., Barton W.A., Jeffrey P.D., et al. Repelling class discrimination: ephrin-a5 binds to and activates ephb2 receptor signaling. Nat. Neurosci. 7 (2004) 501-509
8. Davy A., and Soriano P. Ephrin signaling in vivo: look both ways. Dev. Dyn. 232 (2005) 1-10
9. Munthe E., Finne E.F., and Aasheim H.C. Expression and functional effects of eph receptor tyrosine kinase a family members on Langerhans like dendritic cells. BMC Immunol. 5 (2004) 9
10. Martiny-Baron G., Korff T., Schaffner F., Esser N., Eggstein S., Marme D., et al. Inhibition of tumor growth and angiogenesis by soluble ephb4. Neoplasia 6 (2004) 248-257
11. Coulthard M.G., Duffy S., Down M., Evans B., Power M., Smith F., et al. The role of the eph-ephrin signalling system in the regulation of developmental patterning. Int. J. Dev. Biol. 46 (2002) 375-384
12. Hansen S., Norstein J., and Næss Å. Cancer in Norway 2001 (2004), Oslo, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
13. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol. 92 (2004) 927-935
14. Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C., and Hauptmann S. Cd24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 161 (2002) 1215-1221
15. Baekelandt M., Kristensen G.B., Nesland J.M., Trope C.G., and Holm R. Clinical significance of apoptosis-related factors p53, mdm2, and bcl-2 in advanced ovarian cancer. J. Clin. Oncol. 17 (1999) 2061
16. Skirnisdottir I., Seidal T., Gerdin E., and Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int. J. Gynecol. Cancer 12 (2002) 265-276
17. Berclaz G., Flutsch B., Altermatt H.J., Rohrbach V., Djonov V., Ziemiecki A., et al. Loss of ephb4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol. Rep. 9 (2002) 985-989
18. Miyazaki T., Kato H., Fukuchi M., Nakajima M., and Kuwano H. Epha2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer 103 (2003) 657-663
19. Takai N., Miyazaki T., Fujisawa K., Nasu K., and Miyakawa I. Expression of receptor tyrosine kinase ephb4 and its ligand ephrin-b2 is associated with malignant potential in endometrial cancer. Oncol. Rep. 8 (2001) 567-573
20. Egawa M., Yoshioka S., Higuchi T., Sato Y., Tatsumi K., Fujiwara H., et al. Ephrin b1 is expressed on human luteinizing granulosa cells in corpora lutea of the early luteal phase: the possible involvement of the b class eph-ephrin system during corpus luteum formation. J. Clin. Endocrinol. Metab. 88 (2003) 4384-4392
21. Liu F.S., Hsieh Y.T., Chen J.T., Ho E.S., Hung M.J., and Lin A.J. Fhit (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia. Gynecol. Oncol. 82 (2001) 283-290
22. Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan F., Bucana C.D., et al. Coexpression of ephrin-bs and their receptors in colon carcinoma. Cancer 94 (2002) 934-939
23. Tang X.X., Brodeur G.M., Campling B.G., and Ikegaki N. Coexpression of transcripts encoding ephb receptor protein tyrosine kinases and their ephrin-b ligands in human small cell lung carcinoma. Clin. Cancer Res. 5 (1999) 455-460
24. Tang X.X., Zhao H., Robinson M.E., Cnaan A., London W., Cohn S.L., et al. Prognostic significance of ephb6, efnb2, and efnb3 expressions in neuroblastoma. Med. Pediatr. Oncol. 35 (2000) 656-658
25. Varelias A., Koblar S.A., Cowled P.A., Carter C.D., and Clayer M. Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer 95 (2002) 862-869
26. Nakada M., Niska J.A., Miyamori H., McDonough W.S., Wu J., Sato H., et al. The phosphorylation of ephb2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 64 (2004) 3179-3185
27. Miao H., Burnett E., Kinch M., Simon E., and Wang B. Activation of epha2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2 (2000) 62-69
28. Noren N.K., Lu M., Freeman A.L., Koolpe M., and Pasquale E.B. Interplay between ephb4 on tumor cells and vascular ephrin-b2 regulates tumor growth. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5583-5588
29. Saito T., Masuda N., Miyazaki T., Kanoh K., Suzuki H., Shimura T., et al. Expression of epha2 and e-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol. Rep. 11 (2004) 605-611
30. Wu D., Suo Z., Kristensen G.B., Li S., Troen G., Holm R., et al. Prognostic value of epha2 and ephrina-1 in squamous cell cervical carcinoma. Gynecol. Oncol. 94 (2004) 312-319
31. Straume O., and Akslen L.A. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-a1/epha2 on melanoma progression. Am. J. Pathol. 160 (2002) 1009-1019
32. Wu Q., Suo Z., Risberg B., Karlsson M.G., Villman K., and Nesland J.M. Expression of ephb2 and ephb4 in breast carcinoma. Pathol. Oncol. Res. 10 (2004) 26-33
33. Hafner C., Bataille F., Meyer S., Becker B., Roesch A., Landthaler M., et al. Loss of ephb6 expression in metastatic melanoma. Int. J. Oncol. 23 (2003) 1553-1559
34. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage iii and stage iv ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
35. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
36. Dodelet V.C., and Pasquale E.B. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19 (2000) 5614-5619
37. Dodelet V.C., Pazzagli C., Zisch A.H., Hauser C.A., and Pasquale E.B. A novel signaling intermediate, shep1, directly couples eph receptors to r-ras and rap1a. J. Biol. Chem. 274 (1999) 31941-31946
38. Hock B., Bohme B., Karn T., Yamamoto T., Kaibuchi K., Holtrich U., et al. Pdz-domain-mediated interaction of the eph-related receptor tyrosine kinase ephb3 and the ras-binding protein af6 depends on the kinase activity of the receptor. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9779-9784
39. Holland S.J., Gale N.W., Gish G.D., Roth R.A., Songyang Z., Cantley L.C., et al. Juxtamembrane tyrosine residues couple the eph family receptor ephb2/nuk to specific sh2 domain proteins in neuronal cells. EMBO J. 16 (1997) 3877-3888
40. Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., and Daniel T.O. Nck recruitment to eph receptor, ephb1/elk, couples ligand activation to c-jun kinase. J. Biol. Chem. 273 (1998) 1303-1308
41. Brunner T.B., Hahn S.M., McKenna W.G., and Bernhard E.J. Radiation sensitization by inhibition of activated ras. Strahlenther. Onkol. 180 (2004) 731-740
42. Kim I.A., Fernandes A.T., Gupta A.K., McKenna W.G., and Bernhard E.J. The influence of ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev. 23 (2004) 227-236
43. Messina S., Leonetti C., De Gregorio G., Affatigato V., Ragona G., Frati L., et al. Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochem. Biophys. Res. Commun. 320 (2004) 493-500
44. Batlle E., Bacani J., Begthel H., Jonkheer S., Gregorieff A., van de Born M., et al. Ephb receptor activity suppresses colorectal cancer progression. Nature 435 (2005) 1126-1130
45. Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O., Tuzmen S., et al. Nonsense-mediated decay microarray analysis identifies mutations of ephb2 in human prostate cancer. Nat. Genet. 36 (2004) 979-983
46. Mao W., Luis E., Ross S., Silva J., Tan C., Crowley C., et al. Ephb2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64 (2004) 781-788
47. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. Epha2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23 (2004) 1448-1456
48. Carles-Kinch K., Kilpatrick K.E., Stewart J.C., and Kinch M.S. Antibody targeting of the epha2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 62 (2002) 2840-2847